These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19506374)

  • 1. The FDA prasugrel review: adjudication of myocardial infarction controversy.
    Serebruany VL
    Cardiology; 2009; 114(2):126-9. PubMed ID: 19506374
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 4. Delays of event adjudication in the TRITON trial.
    Serebruany VL
    Cardiology; 2010; 115(3):217-20. PubMed ID: 20234133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook.
    Serebruany VL
    Cardiovasc Revasc Med; 2011; 12(2):94-8. PubMed ID: 21421187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Thomas D; Giugliano RP
    Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017
    [No Abstract]   [Full Text] [Related]  

  • 8. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
    Serebruany VL
    Cardiology; 2008; 111(4):265-7. PubMed ID: 18434736
    [No Abstract]   [Full Text] [Related]  

  • 10. P2Y12 antagonism: promises and challenges.
    Michelson AD
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s33-8. PubMed ID: 18174449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
    Serebruany V
    Thromb Haemost; 2010 Feb; 103(2):415-8. PubMed ID: 20126838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Lazar LD; Lincoff AM
    Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
    Serebruany VL; Alberts MJ; Hanley DF
    Cerebrovasc Dis; 2008; 26(1):93-4. PubMed ID: 18547948
    [No Abstract]   [Full Text] [Related]  

  • 14. Prasugrel, a new platelet inhibitor.
    Yee D; Meyer J; Caliendo G; Oviedo V
    Mt Sinai J Med; 2010; 77(3):315-23. PubMed ID: 20506458
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late prasugrel benefit in STEMI patients?
    Serebruany VL
    Am J Ther; 2009; 16(6):469-70. PubMed ID: 19531932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
    Armani AM
    Crit Pathw Cardiol; 2010 Dec; 9(4):199-202. PubMed ID: 21119337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future of oral antiplatelet therapy: four challenged hypotheses.
    Serebruany VL; Makarov LM
    Thromb Haemost; 2009 Jun; 101(6):1041-3. PubMed ID: 19492145
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
    Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.